Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 3/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131539 | 0.90 | TP53 (0.36) | TP53HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL18329002 | 0.88 | NPSR1 (0.34) | TP53HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL12608681 | 0.87 | WEE1 (0.43) | TP53WEE1CNR2CHEK1 | |
| SCHEMBL18328995 | 0.84 | TP53 (0.40) | TP53HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16131566 | 0.82 | TP53 (0.51) | TP53HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16131540 | 0.78 | TP53 (0.35) | TP53HPGDALDH1A1LMNAMAPT | |
| SCHEMBL13637211 | 0.77 | WEE1 (0.46) | TP53WEE1CNR2CHEK1 | |
| SCHEMBL18328950 | 0.76 | ALDH1A1 (0.40) | HPGDALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL12608667 | 0.76 | WEE1 (0.40) | TP53WEE1KDRCNR2CHEK1 | |
| SCHEMBL18328993 | 0.74 | DYRK1A (0.43) | ALDH1A1KDM4EHTTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | TP53 13/4885HPGD 71/4885ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.